Noxopharm Limited (ASX: NOX)
Noxopharm Limited (ASX: NOX) is aiming to develop a drug to treat cancer in an innovative way that will bring significant change to the management of cancer. www.noxopharm.com
Noxopharm’s idronoxil could potentially prevent COVID-19 fatalities, clinical trials to begin
Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idrono...
Noxopharm receives FDA investigational new drug approval for Veyonda
Oncology drug development company Noxopharm (ASX: NOX) has received FDA investigational new drug (IND) approval for using its Veyonda in combina...
Noxopharm reports positive interim clinical trial results for cancer drug Veyonda
Biotech company Noxopharm’s (ASX: NOX) came out of a trading halt this morning with positive interim results from its LuPIN phase I/II clinical ...
Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m
Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will no...
Noxopharm clinical data shows potential for major new treatment of late-stage prostate cancer
Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 phase 1b trial treating men with late-st...
Noxopharm confirms durable anti-cancer effect from lead drug Veyonda
Anti-cancer drug developer Noxopharm (ASX: NOX) has set the stage to present its highly-anticipated clinical data to the Clinical Oncology Socie...
Noxopharm releases positive interim results from prostate cancer drug study using radioactive therapy
Australian biotech drug developer Noxopharm (ASX: NOX) has reported positive interim results from its LuPIN study involving the Veyonda drug dev...
Noxopharm reports interim ‘clinical benefits’ in treating prostate cancer with Veyonda
Noxopharm (ASX: NOX) has reported interim clinical benefits from an ongoing 24-week trial combining its Veyonda drug with radiotherapy in treati...
Noxopharm and Nyrada discover ‘major development’ for treatment of autoimmune diseases
Biotech drug developer Noxopharm (ASX: NOX) has made an important drug discovery which could potentially help the company develop a treatment th...
Pre-clinical data suggests Noxopharm’s anti-cancer drug can boost radiation effect on paediatric brain cancer
Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation when tr...
Noxopharm hopeful tumour treatment can help reverse late-stage metastatic cancer
Chief executive Dr Graham Kelly has shared his hope drug developer Noxopharm’s (ASX: NOX) NOX66 therapeutic could be a major advance in the trea...
Noxopharm looks to remove toxic assumptions from chemotherapy
Biotech drug developer Noxopharm (ASX: NOX) has presented its most-recent clinical data from its groundbreaking CEP-1 clinical study, at the ESM...
Noxopharm to commence NOX66 cancer study at St Vincent’s Hospital
Noxopharm (ASX: NOX) has announced the involvement of its experimental drug, NOX66, in a clinical study looking at the ability of a pioneering f...